All In Biotech

NDA 213464 · Bayer Healthcare

Lampit

Nifurtimox · Oral

NovelAccelerated approvalPriority reviewOrphan

Last checked: Nov 19, 2026Latest source record: Jun 2, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2020

Aug 6, 2020

Approved uses

2

Original approval plus efficacy supplements

Registered trials

15

6 Phase 3, 0 recruiting

FAERS reports

26

21 serious, 3 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 3, 2026.

LAMPIT is indicated in pediatric patients (birth to less than 18 years of age and weighing at least 2.5 kg) for the treatment of Chagas disease (American Trypanosomiasis) caused by Trypanosoma cruzi [see Clinical Studies ( 14 )]. LAMPIT is a nitrofuran antiprotozoal, indicated in pediatric patients (birth to less than 18 years of age and weighing at least 2.5 kg) for the treatment of Chagas disease (American Trypanosomiasis), caused by Trypanosoma cruzi . ( 1 )

Mechanism: Nifurtimox is an antiprotozoal drug [see Microbiology ( 12.4 )] . Mechanism of Action The mechanism of action of nifurtimox is not fully understood. Studies suggest that nifurtimox is metabolized/activated, by Type I (oxygen insensitive) and Type II (oxygen sensitive) nitoreductases (NTR) leading to production of toxic intermediate metabolites and/or reactive oxygen species that induce DNA damage and cell death of both intracellular and extracellular forms of T. cruzi .

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 2, 2023 Supplement 5 · Efficacy OrphanLetterLabel
  • Aug 6, 2020 Original approval · Type 1 - New Molecular Entity · priority review NovelAccelerated approvalOrphanLabelLetterReview
2 products under this application
  • LAMPIT · NIFURTIMOX 120MG · TABLET, ORAL · Prescription
  • LAMPIT · NIFURTIMOX 30MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Nifurtimox" as an intervention, any sponsor and status, largest first.

All 15 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • nausea9
  • asthenia7
  • dysmetria6
  • vision blurred6
  • headache4
  • diarrhoea3
  • pyrexia3
  • vomiting3
  • abdominal pain2
  • drug rash with eosinophilia and systemic symptoms2
  • dyspnoea2
  • eosinophilia2

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20073
20091
20101
20112
20184
20192
20202
20215
20222
20232
20262

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 54 on PubMed

Sponsor: Bayer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.